Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.

Biochimica et biophysica acta. Reviews on cancer - 1 May 2024

Kitagawa Yosuke, Kobayashi Ami, Cahill Daniel P, Wakimoto Hiroaki, Tanaka Shota

Abstract excerpt

Gliomas with Isocitrate dehydrogenase (IDH) mutation represent a discrete category of primary brain tumors with distinct and unique characteristics, behaviors, and clinical disease outcomes. IDH mutations lead to aberrant high-level production of the oncometabolite D-2-hydroxyglutarate (D-2HG), which act as a competitive inhibitor of enzymes regulating epigenetics, signaling pathways, metabolism, and various...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Glioma

Share to Glutarates

Share to Isocitrate Dehydrogenase

Share to Molecular Targeted Therapy

Share to Mutation

Source

Identifiers

PMID: 38653436
DOI: 10.1016/j.bbcan.2024.189102

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.PMID 38653436Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.Semantic proximity Read ↗

Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.Semantic proximity Read ↗

Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-MutationsSemantic proximity Read ↗

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.Semantic proximity Read ↗

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical ImplicationsSemantic proximity Read ↗

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical ImplicationsSemantic proximity Read ↗

Isocitrate dehydrogenase 1 and 2 mutations in gliomas.Semantic proximity Read ↗

IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?Semantic proximity Read ↗

Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic StrategiesSemantic proximity Read ↗

Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations.Semantic proximity Read ↗

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.